Jaisamrarn 2006.

Methods	Multi‐centre RCT Central computer‐generated randomization schedule used for allocation Described as open label trial
Participants	Country: Thailand (4 sites) Mean age: 34.6 years Number of participants: 169 women were randomized and 167 completed the trial Inclusion criteria: aged between 18 and 45 years, regular menstrual cycle (21 to 35 days), serum progesterone during 5 to 9 days before menstruation of ≥ 5.0 ng/mL, PBAC score > 130 during run‐in phase, no contraindication to treatment drugs, normal renal and liver function, normal pelvic examination Exclusion criteria: concomitant diseases, organic disease, VTE, haemorrhagic or fibrinolytic disorder, hormone therapy during last 3 months, taking any medication that might affect MBL, need or desire for contraception, need for iron supplementation, inability to comply and no consent
Interventions	(1) TXA 3 g daily on days 1 to 5 of cycle (2) MFA 1.5 mg daily on days 1 to 5 of cycle (3) NET 10 mg daily on days 19 to 26 of cycle, for 2 consecutive cycles
Outcomes	MBL using PBAC (end scores) Cure rate (success rate) (defined as PBAC ≤ 130) Adverse events QoL using a 'standardized questionnaire' Acceptability of treatment Hb Duration of menstruation
Notes	Unpublished copy of trial sighted, also conference abstract Source of funding not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer‐generated randomization scheme
Allocation concealment (selection bias)	Low risk	Centralised randomization scheme separate from study investigators
Blinding (performance bias and detection bias) All outcomes	High risk	Described as "open label" Potential knowledge of treatment may have influenced the primary outcome of MBL as this was measured by PBAC
Incomplete outcome data (attrition bias) All outcomes	Low risk	Minimal drop‐outs
Selective reporting (reporting bias)	Low risk	All prespecified outcomes reported
Other bias	Low risk	Groups appeared comparable at baseline